432 filings
Page 3 of 22
6-K
rugz635mgy eo92
15 Jul 20
Primary Document
5:29pm
6-K
0erpt jmzl9xxlhez
2 Jul 20
Primary Document
11:09am
6-K
2mg96 bg2p7e2
29 May 20
Primary Document
5:28pm
6-K
z8slfk
10 Apr 20
Intellipharmaceutics Provides Timing of First Quarter 2020 Results
12:00am
6-K
opwjlmduiv63ynwm
28 Feb 20
Primary Document
4:42pm
6-K
6mr e5k6l
28 Feb 20
Primary Document
4:40pm
6-K
t2k0in b35ivxtonyo
5 Feb 20
Intellipharmaceutics Announces Resignation of Chief Financial Officer
5:04pm
6-K
w1qy7g9a80t2gh 2d
16 Jan 20
Primary Document
8:09am
424B3
4os2nxygp0y
7 Jan 20
Prospectus supplement
2:33pm
424B3
xbzq0r2o8a
7 Jan 20
Prospectus supplement
2:30pm
6-K
u5khsl8 ll
5 Dec 19
Primary Document
9:36am
6-K
3zr0ag
25 Nov 19
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
4:39pm
6-K
bv3xb
18 Nov 19
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing
4:38pm
6-K
mmm48kuty6nlzb42p2t
7 Nov 19
Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval
4:20pm
6-K
d72te
24 Oct 19
Intellipharmaceutics Update on its Oxycodone ER New Drug Application
1:48pm
6-K
fgiq6bva 7eo7z7s24
11 Oct 19
Primary Document
5:20pm
6-K
93dj9oao0qhi6f09s6
4 Oct 19
Intellipharmaceutics Announces an Update in the Purdue Litigation
8:07am
6-K
70h79koqpe4ogod
5 Sep 19
Primary Document
1:44pm
6-K
xsiik6 xx
15 Aug 19
Primary Document
3:28pm